Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Top Cited Papers
- 15 July 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (14), 3312-3322
- https://doi.org/10.1200/jco.2001.19.14.3312
Abstract
PURPOSE: To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD) and topotecan in patients with epithelial ovarian carcinoma that recurred after or didn’t respond to first-line,...Keywords
This publication has 30 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Topotecan in Platinum- and Paclitaxel-Resistant Ovarian CancerGynecologic Oncology, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST MethodThe American Statistician, 1995
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancerGynecologic Oncology, 1992
- Effect of liposomes on P-glycoprotein function in multidrug resistant cellsBiochemical and Biophysical Research Communications, 1992
- Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administrationEuropean Journal of Clinical Pharmacology, 1986